Epigenetic (chemical) modifications to our DNA provide a second layer of information, in addition to the genetic code, which is more dynamic and sensitive to lifestyle factors, the environment and disease. Epigenetic changes are being increasingly adopted as biological markers (biomarkers) for early detection.
For example, the methylation profile of circulating cell free DNA (cfDNA) can be analysed and used to discover novel DNA based methylation biomarkers. However, analysing cfDNA is challenging because it is present in very low amounts (<10ng per standard blood draw) is heavily damaged, and the current approaches have limited compatibility with these uniquely challenging cfDNA samples.
Tagomics has developed an innovative solution for high throughput and cost-effective epigenetic biomarker discovery. Their proprietary enzymatic chemistry allows for highly accurate and simultaneous sequencing of epigenetic modifications, genetic mutations, fragmentomics and other valuable diagnostic insights.
The company’s first product is a liquid biopsy assay for the early detection of colorectal and other common cancers.
Start Codon spun out Tagomics from the University of Birmingham and were joined in this process by initial co-investors, IQ Capital Partners.
For example, the methylation profile of circulating cell free DNA (cfDNA) can be analysed and used to discover novel DNA based methylation biomarkers. However, analysing cfDNA is challenging because it is present in very low amounts (<10ng per standard blood draw) is heavily damaged, and the current approaches have limited compatibility with these uniquely challenging cfDNA samples.
Tagomics has developed an innovative solution for high throughput and cost-effective epigenetic biomarker discovery. Their proprietary enzymatic chemistry allows for highly accurate and simultaneous sequencing of epigenetic modifications, genetic mutations, fragmentomics and other valuable diagnostic insights.
The company’s first product is a liquid biopsy assay for the early detection of colorectal and other common cancers.
Start Codon spun out Tagomics from the University of Birmingham and were joined in this process by initial co-investors, IQ Capital Partners.
Total raised: $8.48M
Investors 2
| Date | Name | Website |
| - | Start Codo... | startcodon... |
| - | IQ Capital... | iqcapital.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.02.2024 | - | $8.48M | - |
Mentions in press and media 5
| Date | Title | Description |
| 18.06.2025 | Tagomics unveils £1.2m project for earlier detection of colorectal cancer | - |
| 20.11.2024 | Tagomics announces a multiomic profiling co-marketing agreement with Agilent | Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis Cambridge, UK, 20 November 2024: Tagomics Ltd., a pioneering biomarker discovery and diagnostic... |
| 22.02.2024 | Tagomics: Disease diagnosis firm bags £6.7m in funding for cancer research | - |
| 21.02.2024 | Tagomics Raises £6.7M in Funding | Tagomics, a Cambridge, UK-based developer of a platform for comprehensive disease insight and diagnosis, raised £6.7M in funding. The round was led by Calculus Capital, with participation from Illumina Ventures, IQ Capital, Agilent Ventures... |
| - | Tagomics | “Tagomics – Working to transform disease diagnosis through comprehensive epigenomic profiling” |